ClinicalTrials.gg
Active, not recruitingNCT06863961Updated Nov 4, 2026

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Afimkibart and Placebo in Atopic Dermatitis, sponsored by Hoffmann-La Roche. Active, not recruiting at 52 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Nov 4, 20264 sites added12 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
200th of 544
162 · median 96
Started
2025
with 40 others
Phase 2
202 of 639
18 open now
Primary completion
2026-07
later than 16 of 115 live
Registered
579th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 200th largest by enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 202 in phase 2, reaches primary completion later than 16 of the 115 other live ones, and was the 579th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AD diagnosis confirmed by a dermatologist according to the Hanifin/Rajka criteria at least 1 year prior to screening
  • Moderate to severe AD
  • At least once daily use of an additive-free, bland emollient for at least 7 days prior to the baseline visit and during the study

Exclusion criteria

Exclusion Criteria:

  • Evidence of other skin conditions that would interfere with the assessment of AD, including, but not limited to, for example cutaneous T-cell lymphoma, allergic contact dermatitis
  • IV, IM, IL, and oral (inhaled, ophthalmic drops, and nasal corticosteroids are allowed) within 4 weeks of the baseline visit and during the study
  • Topical treatment for AD including, but not limited to topical corticosteroids, topical calcineurin Inhibitors, topical PDE-4 inhibitors, , prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea or filaggrin within 7 days prior to the baseline visit and during the study
  • Any active infection or other active skin diseases that required treatment with parenteral anti-infectives within 4 weeks or oral anti-infective treatment within 2 weeks prior to baseline
  • Acquired or congenital immunodeficiency
  • Systemic therapies that are also used in the treatment of AD, including, but not limited to methotrexate, cyclosporine, azathioprine, mycophenolate mofetil within 4 weeks of the baseline visit and during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Afimkibart Group I

    Participants will receive afimkibart via subcutaneous (SC) injection.

    Drug: Afimkibart

  • Experimental
    Afimkibart Group II

    Participants will receive afimkibart via SC injection.

    Drug: Afimkibart

  • Experimental
    Afimkibart Group III

    Participants will receive afimkibart via SC injection.

    Drug: Afimkibart

  • Placebo comparator
    Placebo

    Participants will receive placebo via SC injection.

    Drug: Placebo

Interventions

  • Afimkibart will be administered as SC injection.

    Also known as: PF-06480605, RVT-3101, RO7790121

  • DrugPlacebo

    Placebo will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve Eczema Area and Severity Index-75 (EASI-75) Response (>= 75% Improvement from Baseline) at Week 16

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Percentage of Participants who Achieve Investigator Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) with >= 2-Grade Improvement at Week 16 and Week 32

    Time frame: At Week 16 and Week 32

  2. Percentage of Participants who Achieve EASI-75 Response at Week 32

    Time frame: At Week 32

  3. Percentage of Participants who Achieve EASI-90 Response at Week 16 and Week 32

    Time frame: At Week 16 and Week 32

  4. Percent Change from Baseline in EASI by Visit

    Time frame: Baseline up to end of study (approximately 1 year)

  5. Percent Change from Baseline in Peak Pruritus Numerical Rating Scale (NRS) Score by Visit

    Time frame: Baseline up to end of study (approximately 1 year)

  6. Change from Baseline in Dermatology Quality of Life Index at Week 16, Week 32 and by Visit

    Time frame: Baseline, weeks 4, 10, 16, 22 and 32

  7. Percentage of EASI-75 Responders at Week 16

    Time frame: At Week 16

  8. Percentage of Participants with Adverse Events

    Time frame: Baseline up to end of study (approximately 1 year)

  9. Serum Concentration of Afimkibart at Specified Timepoints

    Time frame: Weeks 0, 2, 4, 6, 10, 14, 16, 18, 22, 26, 30, 32 and monthly at weeks 4, 8 and 12 after treatment discontinuation.

07

Study locations

52 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jul 2026, 15 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 15 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 7, 2025
StartActual
Apr 1, 2025
Primary completionActual
Jul 22, 2026
CompletionEst.
Jan 30, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 12 sites removed
Show 4 added (2 United States, 1 Canada, 1 Poland)
  • First OC Dermatology · Fountain Valley, United States
  • Cumberland Skin Center for Clinical Research LLC · Hermitage, United States
  • Centricity Research London Victoria · London, Canada
  • Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski · Krakow, Poland
Show 12 removed
  • The Center for Dermatology Clinical Research · Fremont, United States
  • AMR Fort Myers · Fort Myers, United States
  • Forest Hill Dermatology Group · Kew Gardens, United States
  • Weill Cornell Medicine · New York, United States
  • Dermatology Research Institute Inc. · Calgary, Canada
  • Centricity Research · London, Canada
  • Ryan Clinical Research Inc · Newmarket, Canada
  • Hopital Charles Nicolle · Rouen, France
  • Universitaetsklinikum Freiburg · Freiburg im Breisgau, Germany
  • Hautmedizin Saar · Merzig, Germany
  • Harzklinikum Dorothea Christiane Erxleben GmbH · Quedlinburg, Germany
  • Clinica Universidad de Navarra-Madrid · Madrid, Spain
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    4 sites added, 12 sites removed
    Show 4 added (2 United States, 1 Canada, 1 Poland)
    • First OC Dermatology · Fountain Valley, United States
    • Cumberland Skin Center for Clinical Research LLC · Hermitage, United States
    • Centricity Research London Victoria · London, Canada
    • Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski · Krakow, Poland
    Show 12 removed
    • The Center for Dermatology Clinical Research · Fremont, United States
    • AMR Fort Myers · Fort Myers, United States
    • Forest Hill Dermatology Group · Kew Gardens, United States
    • Weill Cornell Medicine · New York, United States
    • Dermatology Research Institute Inc. · Calgary, Canada
    • Centricity Research · London, Canada
    • Ryan Clinical Research Inc · Newmarket, Canada
    • Hopital Charles Nicolle · Rouen, France
    • Universitaetsklinikum Freiburg · Freiburg im Breisgau, Germany
    • Hautmedizin Saar · Merzig, Germany
    • Harzklinikum Dorothea Christiane Erxleben GmbH · Quedlinburg, Germany
    • Clinica Universidad de Navarra-Madrid · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06863961
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Apr 1, 2025
Primary completion
Jul 22, 2026
Completion
Jan 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion